DBV Technologies - ADR
NASDAQ:DBVT 3:59:07 PM EDT
Market Cap (Intraday) | 250.46M |
Current PE | N/A |
Forward PE | N/A |
2yr Forward PE | N/A |
10-Day MA | $9.02 |
50-Day MA | $9.21 |
200-Day MA | $5.43 |
DBV Technologies - ADR Stock, NASDAQ:DBVT
177-181, avenue Pierre Brossolette, 107 avenue de la Republique, Chatillon, Hauts-de-France 92320
France
Phone: +33.1.55.42.78.78
Number of Employees: 104
Description
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, St�©phane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.